Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02198794 · ClinicalTrials.gov registry record · Phase 3
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
A Phase 3 study, sponsored by Auspex Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 343
- Enrollment target
NCT02198794 is a Phase 3 study that has completed, run by Auspex Pharmaceuticals. The registered enrollment target is 343 participants.
The verdict
NCT02198794, a Phase 3 study, has completed, sponsored by Auspex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 343 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.
Interventions
- DRUG Placebo
- DRUG SD-809
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2014-10-20 |
| Est. Completion | 2020-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02198794
The ClinicalTrials.gov registry entry for NCT02198794 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auspex Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02198794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02198794 about?
NCT02198794 is a clinical study titled "Reducing Involuntary Movements in Participants With Tardive Dyskinesia". The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of...
What is the current status of trial NCT02198794?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 343 participants. The study started on 2014-10-20. Estimated completion is 2020-12-14.
What interventions are being tested in trial NCT02198794?
The interventions under investigation include: Placebo (DRUG), SD-809 (DRUG).
Who is sponsoring clinical trial NCT02198794?
This trial is sponsored by Auspex Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.